|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kato H, Sato S, Yoneyama M, et al: Cell
type-specific involvement of RIG-I in antiviral response. Immunity.
23:19–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Besch R, Poeck H, Hohenauer T, et al:
Proapoptotic signaling induced by RIG-I and MDA-5 results in type I
interferon-independent apoptosis in human melanoma cells. J Clin
Invest. 119:2399–2411. 2009.PubMed/NCBI
|
|
5
|
Sun HC, Tang ZY, Wang L, et al:
Postoperative interferon alpha treatment postponed recurrence and
improved overall survival in patients after curative resection of
HBV-related hepatocellular carcinoma: a randomized clinical trial.
J Cancer Res Clin Oncol. 132:458–465. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clavien PA: Interferon: the magic bullet
to prevent hepatocellular carcinoma recurrence after resection? Ann
Surg. 245:843–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taniguchi T and Takaoka A: A weak signal
for strong responses: interferon-alpha/beta revisited. Nat Rev Mol
Cell Biol. 2:378–386. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Der SD, Zhou A, Williams BR and Silverman
RH: Identification of genes differentially regulated by interferon
alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad
Sci USA. 95:15623–15628. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schindler C, Shuai K, Prezioso VR and
Darnell JE Jr: Interferon-dependent tyrosine phosphorylation of a
latent cytoplasmic transcription factor. Science. 257:809–813.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Muller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chawla-Sarkar M, Lindner DJ, Liu YF, et
al: Apoptosis and interferons: role of interferon-stimulated genes
as mediators of apoptosis. Apoptosis : an international journal on
programmed cell death. 8:237–249. 2003. View Article : Google Scholar
|
|
12
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
|
|
14
|
Jonasch E and Haluska FG: Interferon in
oncological practice: review of interferon biology, clinical
applications, and toxicities. Oncologist. 6:34–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bekisz J, Baron S, Balinsky C, Morrow A
and Zoon KC: Antiproliferative properties of type I and type II
interferon. Pharmaceuticals. 3:994–1015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rao JS, Yamamoto M, Mohaman S, et al:
Expression and localization of 92 kDa type IV
collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp
Metastasis. 14:12–18. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hou J, Zhou Y, Zheng Y, et al: Hepatic
RIG-I predicts survival and interferon-alpha therapeutic response
in hepatocellular carcinoma. Cancer Cell. 25:49–63. 2014.
View Article : Google Scholar
|
|
19
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bjorklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
21
|
Lamar JM, Pumiglia KM and DiPersio CM: An
immortalization-dependent switch in integrin function up-regulates
MMP-9 to enhance tumor cell invasion. Cancer Res. 68:7371–7379.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ugarte-Berzal E, Redondo-Munoz J, Eroles
P, et al: VEGF/VEGFR2 interaction down-regulates matrix
metalloproteinase-9 via STAT1 activation and inhibits B chronic
lymphocytic leukemia cell migration. Blood. 115:846–849. 2010.
View Article : Google Scholar
|
|
23
|
Ma Z, Qin H and Benveniste EN:
Transcriptional suppression of matrix metalloproteinase-9 gene
expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha.
J Immunol. 167:5150–5159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yen JH, Kong W and Ganea D: IFN-beta
inhibits dendritic cell migration through STAT-1-mediated
transcriptional suppression of CCR7 and matrix metalloproteinase 9.
J Immunol. 184:3478–3486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bruix J and Sherman M; American
Association for the Study of Liver Disease. Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee JS, Chu IS, Heo J, et al:
Classification and prediction of survival in hepatocellular
carcinoma by gene expression profiling. Hepatology. 40:667–676.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Budhu A, Jia HL, Forgues M, et al:
Identification of metastasis-related microRNAs in hepatocellular
carcinoma. Hepatology. 47:897–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fingleton B: Matrix metalloproteinases:
roles in cancer and metastasis. Front Biosci. 11:479–491. 2006.
View Article : Google Scholar
|
|
30
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang P, Yuan W, He J, et al:
Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular
carcinoma: implications for tumor progression and prognosis.
Hepatol Res. 39:1169–1177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeuchi O and Akira S: Pattern
recognition receptors and inflammation. Cell. 140:805–820. 2010.
View Article : Google Scholar : PubMed/NCBI
|
